Trulieve Cannabis Corp. quarterly report, Q1 FY2024

Business context and reporting period

Trulieve Cannabis Corp. is a vertically integrated U.S. cannabis operator with licensed operations in nine states. This unaudited Form 10-Q covers the three months ended March 31, 2024; comparisons are with the three months ended March 31, 2023 unless otherwise noted. The company reported 195 dispensaries and 16 cultivation and processing facilities at quarter-end. Massachusetts and Nevada results are presented as discontinued operations.

Financial performance and position

MetricQ1 2024Q1 2023 / comparison
Revenue$297.6 million$285.2 million; up 4.3%
Gross profit / margin$173.8 million / 58.4%$150.2 million / 52.7%
Operating income / margin$46.1 million / 15.5%$17.2 million / 6.0%
Net loss from continuing operations$23.5 million$34.3 million
Net loss attributable to common shareholders$23.1 million$64.1 million
Adjusted EBITDA (non-GAAP)$105.8 million$78.1 million; up 35.5%
Operating cash flow$139.2 million$0.4 million
Capital expenditures and software purchases$20.6 million$15.8 million

Retail revenue was $285.0 million and wholesale revenue was $12.2 million. Gross-margin improvement reflected cultivation cost efficiencies, including at the Florida production facility, and Maryland adult-use sales.

At March 31, 2024, cash and cash equivalents were $320.3 million (plus $6.6 million restricted cash); current assets were $585.3 million and current liabilities were $117.2 million. Total liabilities were $1.43 billion. Private placement notes had $368.0 million principal outstanding, due October 2026, at an 8.00% stated rate; other notes payable totaled $120.8 million. Construction finance liabilities were $138.0 million. The $368.0 million private-note maturity is a major scheduled obligation.

Material changes and unusual items

  • Revenue grew $12.4 million, supported by additional dispensaries, improved customer traffic and units sold, and Maryland adult-use sales. Store count increased from 181 to 195 year over year.
  • Cost of goods sold fell 8.3% to $123.8 million, lifting gross margin by 5.7 percentage points. Operating income increased $28.9 million.
  • Net interest expense declined $6.5 million, mainly following $187 million of debt retirements in September and December 2023.
  • Income tax provision was $55.4 million despite $31.9 million of pretax income, producing a 174% effective tax rate. The filing cites higher gross margin, a one-time deferred-tax revaluation from changes to certain state tax filing methods, and interest on uncertain tax positions.
  • Uncertain tax position liabilities rose $97.6 million to $278.0 million; $247.3 million relates to the company’s Section 280E tax positions. The company says it believes it does not owe taxes attributable to Section 280E. It had $154.7 million of tax payments on deposit that would reduce the liability when ultimately paid to tax jurisdictions.
  • Operating cash flow benefited materially from a $97.6 million increase in uncertain tax position liabilities and the company’s tax position, as well as improved gross profit. Cash paid for income taxes, net of refunds, was a net refund of $54.9 million.
  • Quarterly net loss included a $1.4 million discontinued-operations loss, versus $31.3 million a year earlier, when discontinued operations recorded substantial impairment charges. Adjusted EBITDA is non-GAAP and includes adjustments such as campaign contributions, share-based compensation and other items.

Outlook, risks and contingencies

Management gave no specific revenue or earnings guidance. It said existing cash should cover anticipated requirements for at least the next 12 months, with potential additional funding from operations, debt or equity offerings. Management’s outlook depends in part on its view that certain Section 280E taxes are not owed; the related tax positions remain uncertain.

After quarter-end, the Florida Supreme Court placed an adult-use cannabis initiative on the November 5, 2024 ballot; passage requires 60% voter approval. On April 30, 2024, the U.S. Department of Justice recommended rescheduling marijuana from Schedule I to Schedule III, which would begin a formal rulemaking process once published in the Federal Register. These developments are not reported as completed changes in law.

Risks include federal cannabis illegality, regulatory and licensing uncertainty, competition, restricted banking access, tax exposure, significant indebtedness, and the possibility that expected market or regulatory changes do not occur. The company reported no pending or threatened lawsuit expected to materially affect results, but recorded $4.2 million for pending litigation contingencies. Material weaknesses in internal control over financial reporting relating to information technology and inventory valuation remained unremediated at March 31, 2024; management said remediation was underway and controls were not yet effective.

Important facts for investors to verify

  • Developments in the Section 280E tax positions, including potential assessments, outcomes, payment timing and availability of the $154.7 million tax deposit.
  • Ability to refinance or repay the $368.0 million private placement notes due in October 2026, and debt-service capacity alongside lease and construction-finance commitments.
  • Whether operating cash generation persists after considering tax payments, working-capital needs and capital spending; Q1 cash flow included a large increase in uncertain tax liabilities.
  • Progress and testing required to remediate the disclosed internal-control material weaknesses.
  • Outcome and timing of Florida’s adult-use ballot measure and the federal rescheduling rulemaking process.
  • Performance of Maryland adult-use sales, Florida cost efficiencies, and the company’s ability to sustain revenue growth and gross margins.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.